JNJ
Johnson & JohnsonPrevious close
273.20
Change
−2.00 / −0.73%
P/E (TTM) ?
41.3
Market Cap
$666B
1M
+3.20%
S&P 500 −0.91% over same period
Volume / Avg Volume
9.0M / 7.0M
1.29× average
Latest earnings analysisFY2026 Q2Reported 2026-07-15
Johnson & Johnson Q2 2026: sales up 6.6%, outlook raised to $101.1B
Johnson & Johnson's second quarter was a beat-and-raise: sales rose 6.6% to $25.31 billion, adjusted EPS of $2.90 topped the $2.87 consensus, and management lifted full-year reported sales guidance to $101.1 billion at the midpoint. The catch is that GAAP net income was flat and GAAP EPS slipped, so read the quarter on the operational line, not the headline profit number.
Read the full analysis →Revenue$25.31BYoY +6.60%
EPS (non-GAAP)$2.90Beatest. $2.87
Next-quarter revenue guidance$101.10B ±0.3%YoY +299.40%
Next-day move+1.19%
Recent Earnings
Click to read the FinDog analysis| Period | Reported | Revenue | Analysis |
|---|---|---|---|
| FY2026 Q2 Quarter ended 2026-06 | 2026-07-15 | $25.3B | Read analysis → |
| FY2026 Q1 Quarter ended 2026-03 | 2026-04-14 | $24.1B | Pending |
| FY2025 Q4 Quarter ended 2025-12 | 2026-01-21 | $94.2B | Pending |
| FY2025 Q3 Quarter ended 2025-09 | 2025-10-14 | $24.0B | Pending |
| FY2025 Q2 Quarter ended 2025-06 | 2025-07-16 | $23.7B | Pending |
| FY2025 Q1 Quarter ended 2025-03 | 2025-04-15 | $21.9B | Pending |
Decision Panel
Trends · Valuation · Earnings reaction · Guidance credibility — all from company filings and market dataValuation
P/E is at percentile 100 of its 5-year rangeExpensive
5-year range 10.0 – 30.8 · Median 19.9
Last 4 quarters: $7.9B in buybacks + $0 in dividends, 1.18% of market cap combined
P/E (TTM)
41.3
P/B
7.8
P/S
6.7
Dividend Yield
3.12%
Earnings Reaction
Over the last 6 reports, the stock moved ±0.6% on average on the first trading day after, rising 4 times
Most recent +1.19%
Volatility & Correlation
1-year beta -0.20 · Correlation with S&P 500 -0.12Low beta
Annualized volatility 21% vs. 13% for the S&P 500
Insider Trading
View all →Last 90 days · Open-market buys and sells by officers and directors · Amounts in USD millions
Buy 0 · $0.00MSell 5 · $62.0MNet selling $62.0M
- 09-02Schmid TimothyEVP, WW Chair, MedTechSell$9.2M33,597 shares · 2 trades · Avg price 274.74
- 08-17Taubert Jennifer LEVP, WWC. Innovative MedicineSell$4.0M15,000 shares · Avg price 263.36
- 08-13Duato JoaquinCEO and Chairman of the BoardSell$32.2M123,291 shares · 2 trades · Avg price 261.17
- 08-06Forminard ElizabethEVP, Chief Legal OfficerSell$4.1M15,918 shares · 2 trades · Avg price 257.00
- 08-05Duato JoaquinCEO and Chairman of the BoardSell$12.5M48,480 shares · 2 trades · Avg price 258.15
Multi-Quarter Financial Trends
View all quarters →Last 12 quarters · As reported by the company
| Quarter | Revenue ($B) | YoY | Gross Margin | Net Income ($B) | EPS |
|---|---|---|---|---|---|
| FY2026 Q3 | 25.40 | +5.9% | 68.1% | 0.21 | 0.09 |
| FY2026 Q2 | 25.31 | +6.6% | 68.2% | 5.53 | 2.27 |
| FY2026 Q1 | 24.06 | +9.9% | 66.3% | 5.24 | 2.14 |
| FY2025 Q4 | 24.56 | +9.1% | 67.6% | 5.12 | 2.08 |
| FY2025 Q3 | 23.99 | +6.8% | 69.6% | 5.15 | 2.12 |
| FY2025 Q2 | 23.74 | +5.8% | 67.9% | 5.54 | 2.29 |
| FY2025 Q1 | 21.89 | +2.4% | 66.4% | 11.00 | 4.54 |
| FY2024 Q4 | 22.52 | +5.3% | 68.3% | 3.43 | 1.41 |
| FY2024 Q3 | 22.47 | +5.2% | 69.0% | 2.69 | 1.11 |
| FY2024 Q2 | 22.45 | +4.3% | 69.4% | 4.69 | 1.93 |
| FY2024 Q1 | 21.38 | +2.3% | 69.6% | 3.26 | 1.34 |
| FY2023 Q4 | 21.40 | +7.3% | — | 4.05 | 1.67 |
| Ticker | P/E | Revenue YoY | Gross Margin | 1M | View |
|---|---|---|---|---|---|
| JNJ | 41.3 | +5.9% | 68.1% | +3.20% | Bullish |
| LLY | 50.2 | +38.6% | 83.9% | +22.51% | Bullish |
| ABBV | 81.4 | +10.2% | 74.7% | +12.73% | Bullish |
| UNH | 23.0 | +0.4% | 88.1% | +10.87% | Bullish |
| MRK | 117.2 | +5.1% | 73.5% | +2.90% | Neutral |
| TMO | 36.4 | +9.1% | — | +3.25% | Neutral |
| AMGN | 28.5 | +9.5% | 72.0% | +10.56% | Bullish |
| GILD | — | +6.8% | 81.1% | +14.51% | Neutral |
| ABT | 39.1 | +7.8% | 56.2% | +7.46% | Neutral |